Emcure Pharmaceuticals Limited — Investor Meet, 17-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Emcure reported strong Q2 FY26 results: revenues surged 13.4% YoY to INR 2,270 Cr, with PAT up 24% to INR 251 Cr. Domestic growth hit 10.6% (organic ~8.5-9%), while international sales rose 15.8%, driven by Europe (+22.7%) and Canada (+17.5%). EBITDA margin stood at 19.3%. The company partnered with Novo Nordisk for 'Poviztra' (semaglutide) for early entry into India's vast obesity market. Debt increased to INR 837 Cr post Zuventus acquisition, aiming for debt-free status by next year. Management projects 150 bps base margin improvement and sustained double-digit organic growth, focusing on strategic M&A and pipeline expansion.